How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Sell
39
EHC Quote, Financials, Valuation and Earnings
Last price:
$109.96
Seasonality move
:
0.63%
Day range:
$106.58 - $119.64
52-week range:
$82.74 - $123.13
Dividend yield:
0.63%
P/E ratio:
22.17x
P/S ratio:
1.99x
P/B ratio:
5.01x
Volume:
3.8M
Avg. volume:
807.6K
1-year change:
25.49%
Market cap:
$10.8B
Revenue:
$5.4B
EPS (TTM):
$4.84
Analysts' Opinion
-
Consensus RatingEncompass Health has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $131.58, Encompass Health has an estimated upside of 22.65% from its current price of $107.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $125.00 representing -16.52% downside risk from its current price of $107.28.
Fair Value
-
According to the consensus of 11 analysts, Encompass Health has 22.65% upside to fair value with a price target of $131.58 per share.
EHC vs. S&P 500
-
Over the past 5 trading days, Encompass Health has underperformed the S&P 500 by -8.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Encompass Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Encompass Health has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Encompass Health reported revenues of $1.5B.
Earnings Growth
-
Encompass Health has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Encompass Health reported earnings per share of $1.48.
Enterprise value:
14B
EV / Invested capital:
--
Price / LTM sales:
1.99x
EV / EBIT:
14.80x
EV / Revenue:
2.53x
PEG ratio (5yr expected):
0.72x
EV / Free cash flow:
36.15x
Price / Operating cash flow:
28.35x
Enterprise value / EBITDA:
11.15x
Gross Profit (TTM):
$2.3B
Return On Assets:
7.67%
Net Income Margin (TTM):
8.97%
Return On Equity:
18.4%
Return On Invested Capital:
9.36%
Operating Margin:
18.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4.4B | $5B | $5.5B | $1.3B | $1.5B | |
| Gross Profit | $1.8B | $2.1B | $2.3B | $545.9M | $630.9M | |
| Operating Income | $656.2M | $760.7M | $924M | $207.5M | $267M | |
| EBITDA | $909.3M | $1.1B | $1.3B | $283.9M | $349.6M | |
| Diluted EPS | $2.70 | $3.70 | $4.84 | $1.10 | $1.48 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1B | $949.7M | $761.7M | $929.8M | $910.9M | |
| Total Assets | $6.5B | $6.9B | $5.7B | $6.2B | $6.6B | |
| Current Liabilities | $812.2M | $754.5M | $592.1M | $680.3M | $856M | |
| Total Liabilities | $4.5B | $4.5B | $3.8B | $3.8B | $3.7B | |
| Total Equity | $2.1B | $2.5B | $2B | $2.4B | $2.9B | |
| Total Debt | $3.3B | $3.3B | $2.7B | $2.7B | $2.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $714.8M | $861.7M | $1.1B | $238.8M | $288.6M | |
| Cash From Investing | -$607.9M | -$628.5M | -$682.1M | -$129.7M | -$158.5M | |
| Cash From Financing | -$142.8M | -$179.8M | -$420.4M | -$40.6M | -$130.4M | |
| Free Cash Flow | $143.8M | $239M | $386.4M | $99.4M | $125.5M | |
EHC
Sector
Market Cap
$10.8B
$34.5M
Price % of 52-Week High
87.13%
49.05%
Dividend Yield
0.63%
0%
Shareholder Yield
1.72%
-1.01%
1-Year Price Total Return
25.49%
-35.15%
Beta (5-Year)
0.901
0.615
Dividend yield:
0.63%
Annualized payout:
$0.47
Payout ratio:
13.12%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$117.15
200-day SMA
Buy
Level
$103.93
Bollinger Bands (100)
Sell
Level
100.35 - 120.19
Chaikin Money Flow
Sell
Level
-4M
20-day SMA
Sell
Level
$119.16
Relative Strength Index (RSI14)
Sell
Level
24.12
ADX Line
Sell
Level
28.77
Williams %R
Buy
Level
-95.7369
50-day SMA
Sell
Level
$119.31
MACD (12, 26)
Buy
Level
30.30
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Sell
Level
-5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9644)
Sell
CA Score
(Annual)
Level (-0.4445)
Buy
Beneish M-Score
(Annual)
Level (-2.7488)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.4636)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
Stock Forecast FAQ
In the current month, EHC has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EHC average analyst price target in the past 3 months is $131.58.
-
Where Will Encompass Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Encompass Health share price will rise to $131.58 per share over the next 12 months.
-
What Do Analysts Say About Encompass Health?
Analysts are divided on their view about Encompass Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Encompass Health is a Sell and believe this share price will drop from its current level to $125.00.
-
What Is Encompass Health's Price Target?
The price target for Encompass Health over the next 1-year time period is forecast to be $131.58 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Encompass Health is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EHC?
You can purchase shares of Encompass Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Encompass Health shares.
-
What Is The Encompass Health Share Price Today?
Encompass Health was last trading at $109.96 per share. This represents the most recent stock quote for Encompass Health. Yesterday, Encompass Health closed at $107.28 per share.
-
How To Buy Encompass Health Stock Online?
In order to purchase Encompass Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
61
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
78
SBET alert for Jul 16
SharpLink Gaming [SBET] is up 28.58% over the past day.
Buy
75
MP alert for Jul 16
MP Materials [MP] is up 0.48% over the past day.
Sell
38
NAIL alert for Jul 16
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 2.38% over the past day.
